Derisking And Accelerating Drug Development With Expertise

By Silvia Steyrer-Gruber & David Alvaro, Ph.D, CEO, Coriolis Pharma & Editor in Chief, Pharma's Almanac

Drug developers face increasing pressure to advance complex therapies quickly while keeping risks low. One effective way to do this is by partnering with organizations that combine deep scientific expertise with comprehensive development services. The article highlights how such partners support projects across all stages—from early formulation research to late‑stage development—by offering integrated capabilities in analytics, formulation development, process understanding, and manufacturing‑related activities. This scientific strength helps identify stability challenges, manufacturability issues, and regulatory risks early, preventing costly setbacks later in development.

A tailored, science‑driven approach also ensures that each project receives the right level of technical support based on its needs, whether the focus is scaling up, optimizing product quality, or preparing for regulatory submissions. By combining advanced technologies with experienced scientific teams, these partners help streamline development, improve decision‑making, and accelerate the path from concept to clinical and commercial success.